What Changed in Immuno-Oncology After ASCO
Jun 23, 2026
View online
10 Immunotherapy Posts Not To Miss From ASCO 2026
IMA401-101 Study: First-in-Human TCER IMA401 in Advanced Solid Tumors
AEGEAN Trial: Durvalumab Reshapes the Tumor Microenvironment in Resectable NSCLC
AMBITION Trial: Atezolizumab Added to Paclitaxel and Bevacizumab in HR+/HER2− Advanced Breast Cancer
A-BRAVE Trial: Time-of-Day Administration of Immunotherapy in Triple-Negative Breast Cancer
KEYNOTE-522 Final Analysis: Pembrolizumab Plus Chemotherapy in High-Risk Early-Stage TNBC
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
